Antibody response to heat-inactivated hepatitis B vaccine (CLB-3mg) in hemodialysis patients and occupational risk personnel: a one year follow-up

• Published in: Revista do Instituto de Medicina Tropical de São Paulo
• Main Authors: C. F. T. Yoshida, C. Takahashi, L. A. C. Mercadante, I. F. Camargo, H. G. Schatzmayr
• Format: Article in Journal/Newspaper
• Language: English
• Published: Universidade de São Paulo (USP) 1988
• Subjects: Hepatitis B vaccine; Immune Response; Hemodialysis; Arctic medicine. Tropical medicine; RC955-962; Infectious and parasitic diseases; RC109-216; Arctic
• Online Access: https://doi.org/10.1590/S0036-46651988000100002; https://doaj.org/article/ea417c63e2024e61b70edabf8b9eaf24

Immune response against hepatitis B vaccine (CLB 3mg) was evaluated in 59 hemodialysis patients and 20 occupational risk personnel. Seroconversion was induced in 52.5% and 70.0% respectively. Twelve months after the first dose, 37.5% of patients and 60.0% of occupational risk personnel had detectable anti-HBs level. Antibody level was expressed in sample ratio units (SRU). Considering only the responders, in the patients group 38.7% had a low anti-HBs response (2.1-9.9 SRU) 32.3% a medium response (10-99.9 SRU) and 29.0% a high response (>100 SRU) while in occupational risk personnel these values were 14.3%, 64.3% and 21.4% respectively. The authors suggest the use of HBV vaccines with more elevated HBsAg concentration or a reinforced immunization schedule to improve the anti-HBs response not only for patients but also for healthy persons.